| Ytd | ||
| 1y |
| Open | 8.59 | Prev Close | 8.59 | Low | 8.59 | High | 8.61 | Mkt Cap | 391.22M |
| Vol | 0.00 | Avg Vol | 905.07K | EPS | -0.50 | P/E | -17.22 | Forward P/E | -13.98 |
| Beta | 0.54 | Short Ratio | 13.91 | Inst. Own | 72.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.84 | 200-d Avg | 6.12 | 1yr Est | 20.64 |
YMAB News
After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pi
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisian
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire'
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breac
Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing an
PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mA
NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mA
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher
Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of
Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $2
Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from
Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price
Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14,
MILWAUKEE , Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for p
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Acquisition to Include Naxitamab-gqgk DANYELZA ® ( Naxitamab-gqgk) , Further Broadening SERB's Rare
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
On Friday, 469 companies hit new 52-week lows.
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Monday